In April 2025, supplementary applications (CYHB2550173, CYHB2550174) for Piperacillin Sodium and Tazobactam Sodium for Injection, co-filed with Sinopharm Weiqida, were accepted by CDE, following the acceptance of Amoxicillin Sodium and Clavulanate Potassium for Injection in December 2024.
NEWS
Supplementary applications for Piperacillin Sodium and Tazobactam Sodium for Injection accepted
2025-04-16 · Company News